Towards a molecular microbial blood test for tuberculosis infection

Mycobacterium tuberculosis (Mtb) is a major human pathogen, responsible for an estimated 10.6 million cases of active tuberculosis (TB) and 1.3 million deaths worldwide in 2022.[1] Most adult cases of active TB arise from progression of asymptomatic Mtb infection, whose global prevalence has been estimated at 23%.[2] Risk of progression from infection to disease can be significantly reduced by administration of preventive antimicrobial therapy,[3] and global roll-out of this intervention will be needed to achieve the World Health Organization (WHO) target of TB elimination by 2050.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research